RECRUITING

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Talk to us

Conditions

MesotheliomaNon Small Cell Lung CancerMalignant Peripheral Nerve Sheath TumorsSolid TumorPancreatic AdenocarcinomaAdvanced Solid TumorMTAP DeletionMTAPMalignantPancreas CancerPRMT5Synthetic LethalityNSCLC

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Official Title

A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

Quick Facts

Study Start:2022-06-09
Study Completion:2026-04-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06937970

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
855-907-3286
Clinical.Trials@bms.com
First line of the email MUST contain the NCT# and Site #.
CONTACT

Principal Investigator

Bristol-Myers Squibb
STUDY_DIRECTOR
Bristol-Myers Squibb

Study Locations (Sites)

Mayo Clinic
Phoenix, Arizona, 85054-4502
United States
Sarah Cannon Research Institute (SCRI) - HealthONE Location
Denver, Colorado, 80218-1238
United States
Rocky Mountain Cancer Centers, LLP - Oncology
Lone Tree, Colorado, 80124
United States
Mayo Clinic
Jacksonville, Florida, 32224
United States
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida, 32827
United States
Local Institution - 124
Chicago, Illinois, 60637
United States
Dana-Farber Cancer Institute
Brookline, Massachusetts, 02251
United States
Cancer and Hematology Centers of Western Michigan
Norton Shores, Michigan, 49444
United States
Mayo Clinic
Rochester, Minnesota, 55905
United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901
United States
David H Koch, Memorial Sloan Kettering Cancer Center
New York, New York, 10021
United States
New york cancer and blood specialists - Oncology
Port Jefferson Station, New York, 11776
United States
Local Institution - 125
Chapel Hill, North Carolina, 27599
United States
SCRI
Nashville, Tennessee, 37203
United States
Local Institution - 132
Nashville, Tennessee, 37232-5505
United States
Local Institution - 120
Dallas, Texas, 75235
United States
Texas Oncology - DFW
Fort Worth, Texas, 76104
United States
MDACC
Houston, Texas, 77030
United States
Oncology Consultants - Clinical Research
Houston, Texas, 77030
United States
South Texas Accelerated Research Therapeutics
San Antonio, Texas, 78229
United States
Texas Oncology, P.A. - Oncology
Tyler, Texas, 78503
United States
Virginia Cancer Specialists, PC
Fairfax, Virginia, 22031
United States
Local Institution - 134
Seattle, Washington, 98109
United States
Medical College of Wisconsin - Froedtert Hospital
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: Bristol-Myers Squibb

  • Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-06-09
Study Completion Date2026-04-30

Study Record Updates

Study Start Date2022-06-09
Study Completion Date2026-04-30

Terms related to this study

Keywords Provided by Researchers

  • MTAP Deletion
  • Mesothelioma
  • Non Small Cell Lung Cancer
  • Malignant Peripheral Nerve Sheath Tumors
  • Solid Tumor
  • MTAP
  • Malignant
  • Pancreatic adenocarcinoma
  • Pancreas Cancer
  • PRMT5
  • Synthetic Lethality
  • Advanced Solid Tumor
  • NSCLC

Additional Relevant MeSH Terms

  • Mesothelioma
  • Non Small Cell Lung Cancer
  • Malignant Peripheral Nerve Sheath Tumors
  • Solid Tumor
  • Pancreatic Adenocarcinoma
  • Advanced Solid Tumor